Low-Risk TAVR Clinical Trial Findings Released & Celebrated!

[Vince]

By Adam Pick on March 17, 2019

Finally! We have results for one of the most talked about heart valve clinical trials ever!
On Friday, at the American College of Cardiology (ACC) conference in New Orleans, the results for the low-risk, transcatheter aortic valve replacement (TAVR) were released.
As for the results… Drum roll please…

The results of this clinical trial, known as the PARTNER 3 research study, were quickly applauded, cheered and celebrated!

In fact, words like “game changer” have been used to describe the success of the clinical trial which investigated the use of the SAPIEN 3 device, a non-invasive treatment of aortic stenosis, in low-risk patients. Aortic stenosis is an often mis-diagnosed and under-treated form of heart disease that can be fatal.


Low-Risk TAVR Clinical Trial Findings Released & Celebrated!

 

[Vince]

To view this content we will need your consent to set third party cookies.
For more detailed information, see our cookies page.

Accept third party cookies

 

[Vince]

The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis

aortic valve disease often have a genetic variant in the vitamin D receptor genes that causes them to require much higher doses of vitamin D than other people

The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis - PMC

OBJECTIVE—To test the hypothesis that vitamin D receptor polymorphism is associated with calcific aortic valve stenosis.
DESIGN—The distribution of one polymorphism of the vitamin D receptor (BsmI B/b) was examined in 100 consecutive patients with ...

www.ncbi.nlm.nih.gov